Premium
Hemicrania Continua Responds to Cyclooxygenase‐2 Inhibitors
Author(s) -
Peres Mario F.P.,
Silberstein Stephen D.
Publication year - 2002
Publication title -
headache: the journal of head and face pain
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.14
H-Index - 119
eISSN - 1526-4610
pISSN - 0017-8748
DOI - 10.1046/j.1526-4610.2002.02131.x
Subject(s) - rofecoxib , celecoxib , cyclooxygenase , medicine , anesthesia , pharmacology , chemistry , enzyme , biochemistry
Background.—Hemicrania continua is a primary headache disorder defined by its absolute responsiveness to indomethacin. We report the treatment response to two cyclooxygenase‐2 inhibitors, celecoxib and rofecoxib, in a series of patients with hemicrania continua. Methods.—Fourteen patients were treated, 9 with rofecoxib and 5 with celecoxib. Results.—Three patients in each group had a complete response to treatment. Conclusion.—The cyclooxygenase‐2 inhibitors may represent an alternative to indomethacin in the treatment of hemicrania continua. Their mechanism of action for this potential indication is unknown.